Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01801111 · BASELINE

Baseline characteristics

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment · Source last updated 2018-11-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      138
    units
    Participants
groups
  1. description
    Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.
    id
    BG000
    title
    Alectinib
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.1
          value
          51.5
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          77
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          61
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Analysis was performed on safety population, which included all participants who received at least one dose of alectinib.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      138
    units
    Participants
groups
  1. description
    Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.
    id
    BG000
    title
    Alectinib
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.1
          value
          51.5
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          77
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          61
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Analysis was performed on safety population, which included all participants who received at least one dose of alectinib.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice